Inhibrx Biosciences, Inc.: Q3 FY2026 earnings call
What management said about Q3 FY2026, from the documents filed with the SEC on 13 November 2026: press release. Guidance figures: 2 new. The quarter’s numbers.
Key takeaways
- Q3 net loss widened to $38.7M: Net loss was $38.7 million, or $2.46 per share, basic and diluted, against $35.3 million, or $2.28 per share, a year earlier. Source
- Pfizer license added $2.0M revenue: The company recognized $2.0 million of revenue from a non-exclusive patent license with Pfizer, paid upfront in September 2026. No revenue was recognized in the third quarter of 2025. Source
- Chondrosarcoma readiness advancing on timeline: Commercial readiness for ozekibart in conventional chondrosarcoma is advancing in line with the regulatory review timeline. Source
- Phase 2 expansion adds about 50 patients: The Phase 2 portion, currently enrolling, is expected to add about 50 HPV-positive patients to support a potential accelerated regulatory pathway. Source
- Interest expense rose with loan balance: Total other expense was $7.0 million against $1.4 million, mainly from higher interest on a $275.0 million loan balance versus $100.0 million a year earlier. Source
- Cash reached $199.5 million: Cash and cash equivalents were $199.5 million at September 30, 2026, against $124.2 million at December 31, 2025. Source
“Inhibrx believes this positioning allows ordastobart (INBRX-106) to maximize its costimulatory activity where immune responsiveness and clinical benefit have proven highest.”
Inhibrx Biosciences, Inc., press release
Guidance
| Area | Period | Figure | Against last quarter |
|---|---|---|---|
| Ordastobart (INBRX-106) HNSCC readout Source | Following the Phase 2 expansion | around mid-2027 | |
| Ordastobart (INBRX-106) NSCLC initial results Source | Mid-2027 | mid-2027 | New |
| HexAgon Phase 2 expansion enrollment Source | Phase 2 expansion, currently enrolling | approximately 50 additional patients | New |
What changed from last quarter
- New: The company recognized $2.0 million of license revenue under a non-exclusive patent license agreement with Pfizer. Source
- New: The HexAgon program expansion is focused on HPV-positive head and neck patients, replacing the prior plan to announce PFS data in the third quarter of 2026. Source
- New: Loan balance outstanding rose to $275.0 million, from $175.0 million at the end of the second quarter. Source
Results and revenue
- Q3 net loss widened to $38.7M: Net loss was $38.7 million, or $2.46 per share, basic and diluted, against $35.3 million, or $2.28 per share, a year earlier. Source
- Nine-month net loss $108.8 million: Net loss for the nine months ended September 30, 2026 was $108.8 million, or $6.95 per share, against $107.2 million, or $6.93 per share, a year earlier. Source
- Pfizer license added $2.0M revenue: The company recognized $2.0 million of revenue from a non-exclusive patent license with Pfizer, paid upfront in September 2026. No revenue was recognized in the third quarter of 2025. Source
Pipeline and clinical programs
- Chondrosarcoma readiness advancing on timeline: Commercial readiness for ozekibart in conventional chondrosarcoma is advancing in line with the regulatory review timeline. Source
- NSCLC perioperative readout set mid-2027: Initial Phase 1/2 results of ordastobart in perioperative NSCLC are expected in mid-2027, which management says could extend use beyond head and neck cancer. Source
- Colorectal cohorts started in Q2: In the second quarter of 2026 the company started two additional Phase 1 colorectal cancer cohorts, one second-line with Folfiri and Avastin and one third- or fourth-line with Lonsurf and Avastin.
“This readout is expected to provide important clinical insights to inform future development, demonstrating the potential for ordastobart (INBRX-106) to extend well beyond head and neck cancer into broader solid tumor indications.”
Inhibrx Biosciences, Inc., press release
Ordastobart HexAgon head and neck study
- HexAgon expanded to HPV-positive patients: The HexAgon program expansion is focused on the HPV-positive setting, in combination with pembrolizumab, for head and neck squamous cell carcinoma. Source
- Phase 2 expansion adds about 50 patients: The Phase 2 portion, currently enrolling, is expected to add about 50 HPV-positive patients to support a potential accelerated regulatory pathway. Source
- Expansion readout around mid-2027: The initial readout of the Phase 2 expansion is expected around mid-2027, after which the company plans to align with the FDA on the framework. Source
Operating expenses
- R&D fell on trial enrollment timing: R&D expense was $26.0 million against $28.5 million a year earlier, mainly from lower chondrosarcoma trial costs after enrollment completed and lower personnel costs. Source
- Contract manufacturing rose for BLA work: Contract manufacturing expense increased as the company performs manufacturing activities to support its filing of the Biologics License Application for ozekibart in conventional chondrosarcoma. Source
- G&A rose on launch preparation: G&A expense was $7.8 million against $5.3 million, reflecting pre-commercialization spending on market access, launch and communication materials for ozekibart. Source
Interest and other expense
- Interest expense rose with loan balance: Total other expense was $7.0 million against $1.4 million, mainly from higher interest on a $275.0 million loan balance versus $100.0 million a year earlier. Source
- Nine-month other expense more than quadrupled: Total other expense for the nine months was $14.0 million, against $3.1 million a year earlier. Source
- Oxford loan has further tranches: The July 2026 second amendment with Oxford provides an additional $325.0 million, with $100.0 million funded at signing and up to $225.0 million more at the company's request and Oxford's discretion.
Cash, debt and equity
- Cash reached $199.5 million: Cash and cash equivalents were $199.5 million at September 30, 2026, against $124.2 million at December 31, 2025. Source
- Stockholders' deficit of $85.9 million: Stockholders' equity was a deficit of $85.9 million at September 30, 2026, against equity of $8.0 million at December 31, 2025. Source
- Total liabilities rose to $306.2M: Total liabilities were $306.2 million at September 30, 2026, against $138.5 million at December 31, 2025, with long-term debt, net of $276.7 million. Source
Coming up, as management said on 13 November 2026
- Ewing sarcoma data at CTOS meeting: Updated Phase 1/2 results for ozekibart with irinotecan and temozolomide in refractory Ewing sarcoma are planned for presentation at the CTOS meeting in Seoul. Source
- Phase 3 start after FDA alignment: After the Phase 2 expansion, the company plans to align with the FDA and anticipates starting the Phase 3 portion of HexAgon as the confirmatory study. Source
- Chondrosarcoma PDUFA goal date: The FDA goal date for the ozekibart chondrosarcoma BLA was set in the prior release.
- FDA meeting on colorectal plans: The company planned to meet the FDA in Q4 2026 on a first-line CRC registrational trial and an accelerated pathway in fourth-line CRC.
- Colorectal interim results expected: Interim results from the two new colorectal cohorts were expected in the first quarter of 2027.
Figures management reported
| Figure | Reported |
|---|---|
| R&D expense Source | $26.0 million, third quarter 2026 (vs $28.5 million) |
| License revenue Source | $2.0 million, Pfizer non-exclusive patent license |
| PDUFA goal date | April 14, 2027, ozekibart in conventional chondrosarcoma |
Risks management discussed
- Regulatory: Accelerated pathway for HexAgon depends on the FDA agreeing with the framework after the Phase 2 expansion, and the Phase 3 confirmatory study is still to start. Source
- Financial: Interest cost rises with the larger loan balance, which raised other expense in the quarter. Source
- Operational: Pre-commercialization spending is being incurred ahead of a regulatory decision on ozekibart in chondrosarcoma. Source
Earlier plans management reported on
- Not stated: The prior release planned PFS data in the third quarter of 2026. This release describes the HexAgon expansion and does not report those data.
- On track: Management says commercial readiness for ozekibart in chondrosarcoma is advancing in line with the regulatory review timeline. Source
Other quarters
Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.